OCUL
Ocular Therapeutix Inc
9.80$
-1.8%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | +126.7% | +7.8% | +1.9% | +3.5% | +112.4% | +311.7% | +150.1% | +18.3% | +13.5% | +9.0% | -18.7% | |
| – | +150,142.9% | -99.1% | +250.5% | +38.9% | +3.2% | +1.8% | +400.0% | -10.4% | +111.5% | +3.0% | +16.3% | +6.5% | +16.9% | |
| – | -350,666.7% | – | +110.1% | +0.9% | +1.5% | +4.0% | +24.7% | +705.5% | +155.3% | +20.0% | +13.2% | +9.3% | -22.1% | |
| – | -8.9% | +79.5% | +40.9% | +1.7% | +14.1% | +19.5% | +11.3% | -30.2% | +74.5% | +6.7% | +14.2% | +109.0% | +54.4% | |
| – | +19.2% | +292.6% | +32.6% | +20.1% | +40.9% | +21.1% | +17.8% | +3.3% | +39.5% | +113.2% | -50.1% | +78.7% | +6.1% | |
| – | -5.6% | +115.3% | +42.7% | +13.0% | +41.6% | -4.3% | +44.6% | -10.9% | +49.9% | +7.2% | +7.9% | +69.6% | +37.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +17.0% | +153.7% | +54.1% | -2.6% | +12.6% | -8.1% | +250.8% | +10.9% | -1.4% | +5.3% | +61.5% | +19.7% | -12.8% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +38.7% | -71.4% | +651.5% | -18.3% | -65.9% | -940.4% | – | +12.1% | +6.4% | -279.2% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -2,538.2% | – | – | – |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.